Division of Pediatric Critical Care Medicine, Department of Pediatrics, NY Presbyterian Hospital-Weill Cornell Medicine, New York, NY.
Division of Pediatric Critical Care Medicine, Department of Pediatrics, Children's Hospital of Richmond at VCU, Richmond, VA.
Pediatr Crit Care Med. 2022 Jan 1;23(1):34-51. doi: 10.1097/PCC.0000000000002851.
Critically ill children frequently receive plasma and platelet transfusions. We sought to determine evidence-based recommendations, and when evidence was insufficient, we developed expert-based consensus statements about decision-making for plasma and platelet transfusions in critically ill pediatric patients.
Systematic review and consensus conference series involving multidisciplinary international experts in hemostasis, and plasma/platelet transfusion in critically ill infants and children (Transfusion and Anemia EXpertise Initiative-Control/Avoidance of Bleeding [TAXI-CAB]).
Not applicable.
Children admitted to a PICU at risk of bleeding and receipt of plasma and/or platelet transfusions.
None.
A panel of 29 experts in methodology, transfusion, and implementation science from five countries and nine pediatric subspecialties completed a systematic review and participated in a virtual consensus conference series to develop recommendations. The search included MEDLINE, EMBASE, and Cochrane Library databases, from inception to December 2020, using a combination of subject heading terms and text words for concepts of plasma and platelet transfusion in critically ill children. Four graded recommendations and 49 consensus expert statements were developed using modified Research and Development/UCLA and Grading of Recommendations, Assessment, Development, and Evaluation methodology. We focused on eight subpopulations of critical illness (1, severe trauma, intracranial hemorrhage, or traumatic brain injury; 2, cardiopulmonary bypass surgery; 3, extracorporeal membrane oxygenation; 4, oncologic diagnosis or hematopoietic stem cell transplantation; 5, acute liver failure or liver transplantation; 6, noncardiac surgery; 7, invasive procedures outside the operating room; 8, sepsis and/or disseminated intravascular coagulation) as well as laboratory assays and selection/processing of plasma and platelet components. In total, we came to consensus on four recommendations, five good practice statements, and 44 consensus-based statements. These results were further developed into consensus-based clinical decision trees for plasma and platelet transfusion in critically ill pediatric patients.
The TAXI-CAB program provides expert-based consensus for pediatric intensivists for the administration of plasma and/or platelet transfusions in critically ill pediatric patients. There is a pressing need for primary research to provide more evidence to guide practitioners.
危重症患儿常需输注血浆和血小板。本研究旨在确定有关危重症儿科患者输注血浆和血小板决策的循证推荐意见,当证据不足时,我们制定了基于专家共识的声明。
系统评价和共识会议系列,涉及止血和危重症婴幼儿血浆/血小板输注领域的多学科国际专家(血栓形成和输血专家倡议-控制/避免出血[TAXI-CAB])。
不适用。
有出血风险并接受血浆和/或血小板输注的 PICU 入院患儿。
无。
来自五个国家和九个儿科亚专业的 29 名方法学、输血和实施科学专家组成员完成了系统评价,并参加了一个虚拟共识会议系列,以制定推荐意见。检索包括 MEDLINE、EMBASE 和 Cochrane 图书馆数据库,时间从建库至 2020 年 12 月,使用了主题词和文本词的组合来检索有关危重症儿童血浆和血小板输注的概念。采用改良的研究与开发/加州大学洛杉矶分校和分级评估、制定与评价方法制定了四项分级推荐意见和 49 项共识专家声明。我们重点关注了 8 个危重症亚组人群(1.严重创伤、颅内出血或创伤性脑损伤;2.体外循环手术;3.体外膜氧合;4.肿瘤诊断或造血干细胞移植;5.急性肝衰竭或肝移植;6.非心脏手术;7.手术室外的有创操作;8.脓毒症和/或弥散性血管内凝血)以及实验室检测以及血浆和血小板成分的选择/处理。我们总共就四项推荐意见、五项良好实践声明和 44 项基于共识的声明达成共识。这些结果进一步发展为用于危重症儿科患者血浆和血小板输注的基于共识的临床决策树。
TAXI-CAB 计划为儿科重症监护医生提供了有关危重症儿科患者输注血浆和/或血小板的专家共识。迫切需要开展初级研究以提供更多证据来指导从业者。